Literature DB >> 31626715

LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.

Raquel Blazquez1,2, Eva Rietkötter2, Britta Wenske1,2, Darius Wlochowitz3, Daniela Sparrer1, Elena Vollmer1, Gunnar Müller1, Julia Seegerer1, Xueni Sun4, Katja Dettmer4, Alonso Barrantes-Freer5,6, Lena Stange7, Kirsten Utpatel8, Annalen Bleckmann2,9, Hannes Treiber2,10, Hanibal Bohnenberger11, Christof Lenz12,13, Matthias Schulz2, Christian Reimelt14, Christina Hackl15, Marian Grade16, Deram Büyüktas2, Laila Siam17, Marko Balkenhol18, Christine Stadelmann5, Dieter Kube2, Michael P Krahn19, Martin A Proescholdt20, Markus J Riemenschneider7, Matthias Evert8, Peter J Oefner4, Chistoph A Klein14,21, Uwe K Hanisch5, Claudia Binder2, Tobias Pukrop1,2.   

Abstract

More than half of all brain metastases show infiltrating rather than displacing growth at the macro-metastasis/organ parenchyma interface (MMPI), a finding associated with shorter survival. The lymphoid enhancer-binding factor-1 (LEF1) is an epithelial-mesenchymal transition (EMT) transcription factor that is commonly overexpressed in brain-colonizing cancer cells. Here, we overexpressed LEF1 in an in vivo breast cancer brain colonization model. It shortened survival, albeit without engaging EMT at the MMPI. By differential proteome analysis, we identified a novel function of LEF1 as a regulator of the glutathione (GSH) system, the principal cellular redox buffer. LEF1 overexpression also conferred resistance against therapeutic GSH depletion during brain colonization and improved management of intracellular ROS. We conclude that besides EMT, LEF1 facilitates metastasis by improving the antioxidative capacity of epithelial breast cancer cells, in particular during colonization of the brain parenchyma.
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  LEF1; ROS; brain metastasis; glutathione; metastatic colonization

Mesh:

Substances:

Year:  2019        PMID: 31626715     DOI: 10.1002/ijc.32742

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma.

Authors:  Andrea Martins-da-Silva; Mirella Baroni; Karina Bezerra Salomão; Pablo Ferreira das Chagas; Ricardo Bonfim-Silva; Lenisa Geron; Gustavo Alencastro Veiga Cruzeiro; Wilson Araújo da Silva; Carolina Alves Pereira Corrêa; Carlos Gilberto Carlotti; Rosane Gomes de Paula Queiroz; Suely Kazue Nagahashi Marie; Silvia Regina Brandalise; José Andrés Yunes; Carlos Alberto Scrideli; Elvis Terci Valera; Luiz Gonzaga Tone
Journal:  Cell Mol Neurobiol       Date:  2022-04-02       Impact factor: 5.046

Review 2.  Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer.

Authors:  Qianyang Ni; Meng Li; Suyang Yu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance.

Authors:  Zhimin Xu; Yingxin Zhang; Huanyan Dai; Bing Han
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

4.  High COL10A1 expression potentially contributes to poor outcomes in gastric cancer with the help of LEF1 and Wnt2.

Authors:  Miaozun Zhang; Ming Jin; Zhiqiang Gao; Weiming Yu; Wei Zhang
Journal:  J Clin Lab Anal       Date:  2022-08-05       Impact factor: 3.124

5.  Cinobufagin Suppresses Melanoma Cell Growth by Inhibiting LEF1.

Authors:  Geon-Hee Kim; Xue-Quan Fang; Woo-Jin Lim; Jooho Park; Tae-Bong Kang; Ji Hyung Kim; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

6.  Tumor microenvironment-related multigene prognostic prediction model for breast cancer.

Authors:  Kai Hong; Yingjue Zhang; Lingli Yao; Jiabo Zhang; Xianneng Sheng; Yu Guo
Journal:  Aging (Albany NY)       Date:  2022-01-20       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.